Panacea Biotec has announced the receipt of a Letter of Award from the Central Medical Services Society (CMSS), under the Ministry of Health and Family Welfare, Government of India.
The contract involves the supply of Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP, valued at ₹20.79 crore.
According to the details provided, the supply of the Td Vaccine will be executed in several tranches, commencing from September or October 2026 and continuing until November or December 2028. This significant contract underscores Panacea Biotec's role in contributing to public health initiatives by providing essential vaccines.
The awarding entity, CMSS, is a domestic body under the Indian government, and the contract does not involve any related party transactions, nor does it have any interest from the promoter group or group companies of Panacea Biotec.
This development is a part of Panacea Biotec's ongoing efforts to support vaccination programmes and enhance its portfolio in the healthcare sector. The company's commitment to delivering quality vaccines is reflected in this substantial contract, which aligns with its strategic objectives.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).
This article is written by Yash Agarwal and reviewed by Aman Shukla before publication.